From Lab to Pharmacy: How India's Drug Industry Really Works

What You'll Learn

By the end of this guide, you'll understand:

• How a drug travels from a scientist's notebook to your medicine cabinet
• Every business and stakeholder in India's pharma value chain
• Why India is called the "pharmacy of the world" and what that actually means
• Where investors find moats (and risks) at each stage of the chain

Reading Time: 18 minutes Difficulty Level: Beginner-friendly

---

Why Pharma Is Unlike Any Other Industry

When you buy a biscuit, you know roughly how it's made: someone bakes flour and sugar, packages it, ships it to a store, and you buy it. The chain is short and visible.

Now think about the paracetamol tablet in your medicine cabinet. A chemist in a research lab identified a molecule. A toxicologist tested it on animals. Doctors ran it through three rounds of clinical trials on thousands of patients. A regulatory agency reviewed tens of thousands of pages of data before approving it. A chemical factory synthesised the active ingredient. A manufacturing plant compressed it into a tablet. A distributor shipped it through a three-tier network. A pharmacist dispensed it on a doctor's prescription.

That tablet represents a chain with at least 10 distinct businesses, 4 different regulators, and 12 or more years of work.

This is why pharma is different. And this is why, before you invest in a single pharma stock, you need to understand every link in this chain.

India sits at the centre of global pharma. The industry is worth approximately $68 billion today and is projected to reach $175 billion by 2034. India supplies 20% of global generic medicines by volume, exports to more than 200 countries, and manufactures over 60,000 generic brands across 60 therapeutic categories. One in five generic pills consumed anywhere in the world likely came from an Indian factory.

But the "pharmacy of the world" label covers many very different businesses. An API manufacturer, a clinical-stage biotech, a branded generic company, and a pharmacy chain are all "pharma", but they have completely different risk profiles, moats, and financial characteristics.

Let's walk through the full chain.

---

Stage 1: Drug Discovery

Every medicine starts with a question: "What is causing this disease, and can we find a molecule that fixes it?"

Drug discovery is the most expensive and least predictable part of the chain. Scientists first identify a biological "target" (usually a protein or enzyme involved in a disease). Then they search through libraries of chemical compounds, sometimes millions of candidates, to find one that interacts with that target in a useful way. This process, called screening, is increasingly aided by artificial intelligence and supercomputing.

Once a promising molecule is found, chemists optimise it: tweak its structure to make it more effective, less toxic, more stable. This phase alone can take 3 to 5 years and cost $100 to $200 million, before a single human has been tested.

Who does this work?

Primarily, it is innovator pharma companies: the large multinationals like Pfizer, Roche, Novartis, AstraZeneca, and Eli Lilly. They invest enormous sums in R&D because if they succeed, a patent gives them 20 years of exclusive rights to sell that drug.

In India, most pharma companies have historically been generic manufacturers: they wait for the innovator's patent to expire, then make a cheaper copy. Original drug discovery in India is limited, but it is growing. Companies like Dr. Reddy's, Glenmark, and Sun Pharma's specialty division are investing in novel drug research, though their R&D budgets are still a fraction of global innovator companies.

What about biotech startups? Increasingly, drug discovery happens not inside large pharma companies but at small biotech startups, often spun out of universities. Large companies then acquire these startups, paying billions for a single promising molecule. India's biotech startup ecosystem is nascent but growing, particularly in Hyderabad and Bengaluru.

---

Stage 2: Pre-Clinical Testing

A molecule that looks promising in a computer simulation or a test tube needs to be tested on living organisms before it can go anywhere near a human being. This is pre-clinical testing.

Researchers test the candidate drug on cell cultures and then on animals (typically mice, rats, and sometimes dogs or primates). They are answering three questions: Is it toxic? Does the body absorb and process it correctly? Does it actually have the desired effect in a living system?

Most candidate drugs fail here. Of every 5,000 to 10,000 compounds that enter pre-clinical testing, only about 5 progress to human trials.

Who does pre-clinical work?

Many pharma companies do this in-house, but a large and growing portion is outsourced to CROs (Contract Research Organisations). CROs are specialised research companies that run experiments, manage data, and provide scientific expertise on behalf of pharma clients. Think of them as the outsourced R&D department.

India has a growing CRO industry. Syngene International (a subsidiary of Biocon) is India's largest listed CRO. Global players like IQVIA, Parexel, and Charles River Laboratories also have significant India operations, attracted by India's large pool of trained scientists and costs that are 30 to 40% lower than the US or Europe.

---

Stage 3: Clinical Trials

This is the most expensive and most scrutinised phase. Once a drug passes pre-clinical tests, it must be tested on humans in three sequential phases, each larger and more definitive than the last.

Phase 1: Is It Safe? Small group of 20 to 100 healthy volunteers. Researchers are not yet trying to cure anyone: they are figuring out how the drug behaves in the human body. What is the right dose? How quickly does the body process it? At what point does it become toxic? Duration: 1 to 2 years.

Phase 2: Does It Work? Now the drug is tested on 100 to 500 patients who actually have the target disease. The question shifts from safety to efficacy: does it actually reduce the disease? What side effects appear in sick patients? Duration: 2 to 3 years.

Phase 3: Is It Better Than What Exists? Large-scale trial on 1,000 to 5,000 patients, often run across multiple countries simultaneously. This is the definitive test. The drug is compared against the current standard of care (often a placebo or an existing drug). Regulators will scrutinise every data point from this phase. Duration: 3 to 5 years.

Success rate: Only about 10% of drugs that enter Phase 1 clinical trials ever reach the market. The entire journey from discovery to market approval takes 10 to 15 years on average and costs $1 to $2 billion.

India's role in clinical trials is growing. Multinationals increasingly run Phase 2 and Phase 3 trials at Indian hospitals, both because of cost savings and because India's large, treatment-naive patient population makes it easier to recruit trial participants. Major Indian hospital chains and academic medical centres (AIIMS, CMC Vellore, Tata Memorial) participate in global trials.

---

Stage 4: Regulatory Approval

A drug that completes Phase 3 trials must be approved by a regulatory authority before it can be sold. These agencies exist to verify that a drug is safe and effective based on the clinical evidence: they are the last line of protection for patients.

In India: The Drug Controller General of India (DCGI), operating under the Central Drugs Standard Control Organisation (CDSCO), approves new drugs for the Indian market. Every drug sold in India needs DCGI approval.

For the US market (most important for Indian exporters): The US Food and Drug Administration (FDA). The FDA is the most rigorous drug regulator in the world and the most commercially significant, as the US is the world's largest pharmaceutical market by value.

For an innovator drug, a company files an NDA (New Drug Application), a massive document containing all clinical trial data. For a generic drug, a company files an ANDA (Abbreviated New Drug Application). The "abbreviated" part is key: generic companies do not need to repeat the full clinical trials. They only need to prove bioequivalence, meaning their drug delivers the same amount of active ingredient into the bloodstream in the same timeframe as the original. This is far cheaper and faster, which is the foundation of India's generic drug industry.

For other major markets: The European Medicines Agency (EMA) covers the EU. For developing-country markets (Africa, Southeast Asia), WHO prequalification is often used as a quality benchmark.

US FDA inspections: the risk Indian companies live with

Every Indian pharma plant that wants to export to the US must maintain US FDA-compliant manufacturing standards. The FDA inspects these plants (sometimes announced, sometimes not), and the outcome can have enormous financial consequences.

• Form 483: A list of "observations" (deficiencies the inspector found). Serious, but not immediately punitive. Companies have time to respond and correct issues.
• Warning Letter: The FDA formally declares non-compliance. Until the plant remedies all issues and passes a re-inspection, the FDA will not approve any new generic applications from that facility. This can freeze a company's growth for 12 to 24 months.
• Import Alert: The most severe action. The FDA stops all imports from that facility into the US. Revenue from that plant drops to zero overnight.

---

Stage 5: API Manufacturing

Before a tablet can be made, someone has to make the active molecule itself. This is the API (Active Pharmaceutical Ingredient). It is the chemical that actually does the therapeutic work. Everything else in the tablet (the binding agents, the coating, the colouring) is called an excipient and is pharmacologically inert.

Making APIs is industrial chemistry at a high level of precision. The molecule must be synthesised with exactly the right purity (typically 99.5% or above), because even small impurities can cause side effects or reduce efficacy.

India's position in global API manufacturing is formidable. India produces approximately 20% of global API volumes and is the world's third-largest API manufacturer by volume (after China and the EU). India is particularly strong in antibiotics, cardiovascular drugs, vitamins, and antidiabetic molecules.

Key listed Indian API companies include:

• Divi's Laboratories : India's largest API company, dominant in custom synthesis for global pharma
• Laurus Labs : Strong in antiretroviral (HIV) APIs and increasingly in formulations
• Aarti Industries / Aarti Drugs : Specialty chemicals and pharmaceutical APIs
• Solara Active Pharma Sciences : API specialist

The China dependency problem

India's API industry has a structural vulnerability: for many key starting materials and intermediates (the building blocks of APIs), India depends heavily on China. This came into sharp focus during the COVID-19 pandemic when Chinese supply chains were disrupted. The Indian government has since launched Production-Linked Incentive (PLI) schemes specifically for API manufacturing to reduce this dependency.

Vertical integration as a moat

Some Indian pharma companies have integrated backwards into API manufacturing: they make their own APIs rather than buying from external suppliers. This gives them better margin control and supply chain security. Dr. Reddy's, Aurobindo Pharma, and Divi's are examples of companies with significant in-house API capability.

---

Stage 6: Drug Manufacturing

Once the API exists, it must be turned into a form patients can actually take: a tablet, a capsule, a syrup, an injectable, an inhaler. This process is called formulation.

Formulation is not just mixing an API with chalk and pressing it into a tablet. The science of how a drug releases into the bloodstream (whether it dissolves quickly, releases over 12 hours, or targets a specific part of the body) is sophisticated chemistry. Different formulations (immediate release, extended release, coated, uncoated) can give the same API very different clinical properties.

Manufacturing must comply with GMP (Good Manufacturing Practice), a global quality standard that covers everything from air filtration in the production area to how deviations are documented and investigated. Without GMP certification, a plant cannot export to regulated markets.

CDMOs: the outsourced manufacturers

Not every pharma company wants to own and operate its own manufacturing plants. CDMOs (Contract Development and Manufacturing Organisations) are specialised manufacturers that make drugs on behalf of other companies. A small innovative biotech might develop a drug but outsource all manufacturing to a CDMO.

India's CDMO market was valued at approximately $8.5 billion in 2025 and is growing at 7 to 10% annually. Key Indian CDMOs include:

• Piramal Pharma Solutions: One of India's largest CDMOs, with global customers
• Strides Pharma Science: Specialised in niche formulations and regulated markets
• Aurobindo Pharma: Has both a large in-house formulation business and CDMO operations
• Divi's Laboratories: Primarily API-focused but offers custom synthesis (CDMO-adjacent)

---

Stage 7: The Distribution Chain

Imagine you are Sun Pharma and you have just manufactured 10 million tablets of a cardiovascular drug in your Gujarat plant. How do you get that drug to a chemist shop in Kolkata, a hospital in Coimbatore, and a rural dispensary in Madhya Pradesh?

India has one of the most complex and extensive pharmaceutical distribution networks in the world. It operates on a three-tier structure:

Tier 1: C&F Agents (Clearing and Forwarding Agents) The pharma company appoints a C&F agent in each state. The C&F agent receives bulk stock from the manufacturer, stores it in a state-level warehouse, and dispatches it to distributors across that state. The C&F agent does not take ownership of the goods: it earns a fee for logistics and storage services. A typical mid-sized pharma company runs 12 to 20 C&F agents covering all states and Union Territories.

Tier 2: Distributors and Super Stockists The distributor (also called a super stockist) buys stock from the C&F agent and sells it to retail pharmacies and smaller stockists across their geography. Unlike C&F agents, distributors do take ownership of the goods and earn a margin on resale (typically 7 to 10%). India has approximately 65,000 registered pharmaceutical stockists.

Tier 3: Retail Pharmacies The final point of sale. India has approximately 550,000 retail pharmacy outlets: standalone chemist shops, retail chains like Apollo Pharmacy and MedPlus, and hospital pharmacies. This is where patients (or hospitals) actually buy the drug.

The Medical Representative (MR) network Running parallel to the physical distribution chain is the human network: Medical Representatives, or MRs. These are the sales executives employed by pharma companies to call on doctors, explain products, leave samples, and build prescribing relationships. India's pharma industry employs approximately 500,000 MRs, one of the largest field forces in any industry.

An MR's job is not to sell drugs to doctors. It is to inform prescribers about the company's products, maintain relationships, and influence prescribing habits. A strong MR network is one of the most durable moats in Indian pharma: it takes years to build and is very hard for a new competitor to replicate quickly.

---

Stage 8: The Prescriber

This is the most counterintuitive part of the pharma value chain for first-time observers.

In almost every other consumer industry, the person who pays for a product is also the person who chooses it. You pick your biscuits, your phone, your clothes.

In prescription pharma, the person who pays (the patient) does not choose the product. The prescriber (the doctor) chooses it. The patient simply fills the prescription.

This creates a unique marketing dynamic. Pharma companies do not advertise to patients (for prescription drugs, though OTC products are different). They invest in educating and influencing doctors through MR visits, medical conferences, continuing medical education (CME) programmes, and clinical literature.

Branded generics: the Indian model

India has a distinctive pharma market structure that investors must understand. In most developed countries, doctors prescribe by the molecule name: "prescribe metformin." Pharmacists then dispense the cheapest generic available.

In India, doctors typically prescribe by brand name: "prescribe Glycomet." Even though Glycomet is just metformin (a generic molecule), the patient asks for Glycomet specifically. This means the brand name carries value, and the pharma company that built that brand relationship with the doctor can charge a modest premium over a nameless generic.

This is why "branded generics" (generic molecules sold under branded names with strong doctor relationships) form the core of India's domestic pharma market. It is a durable business model that gives mid-sized Indian pharma companies pricing power on molecules that are technically off-patent.

OTC drugs: a different model

Some drugs do not require a prescription: they are available over the counter (OTC). For OTC products (like Crocin, Vicks, Eno), the patient is the decision-maker, and traditional consumer marketing applies: television advertising, pharmacy shelf placement, brand recognition.

Companies like Mankind Pharma (Gas-O-Fast, Prega News, Manforce) and Cipla (Nicotex) have built significant OTC consumer health portfolios that behave more like FMCG brands than pharmaceutical products.

---

Stage 9: Pharmacies and Hospitals

Retail pharmacy chains India's 550,000 retail pharmacies are mostly small, independent chemist shops. But organised pharmacy retail chains are growing: Apollo Pharmacy (the largest, with 5,500-plus stores), MedPlus (2,000-plus stores), and Wellness Forever. These chains are vertically integrating backward, sourcing directly from manufacturers and stocking their own private-label generics.

Hospital pharmacies Hospitals are a distinct channel, especially important for injectable drugs, oncology medications, and ICU medications. Hospitals maintain a formulary (a list of approved drugs that their pharmacy stocks). Getting onto a major hospital formulary is strategically important for companies selling hospital-use drugs.

Jan Aushadhi stores Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), the government has established over 10,000 Jan Aushadhi stores selling generic drugs at prices 50 to 90% below branded equivalents. This government initiative provides competition at the bottom of the market but is also an acknowledgement that India needs affordable medicines. For investors, Jan Aushadhi is less a direct competitive threat to branded pharma companies (which serve different customer segments) and more a signal of government intent on drug pricing.

Online pharmacies Still a small segment (approximately 2 to 3% of the market) but growing. Platforms like PharmEasy, Netmeds (Reliance), and Tata 1mg are building digital pharmacy businesses. They offer prescription uploads, home delivery, and competitive pricing. Their long-term impact on branded pharma margins is a topic of ongoing debate.

---

Stage 10: The Payer

In most developed countries, insurance companies or government health programmes pay for a large share of drug costs. In India, the picture is different and more complex.

The NPPA and price controls The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of drugs listed on the National List of Essential Medicines (NLEM). The NLEM covers approximately 384 drug formulations: common medicines for infections, heart disease, diabetes, tuberculosis, and other conditions.

For drugs on the NLEM, manufacturers cannot charge above the ceiling price set by the NPPA. The government adjusts these ceiling prices annually, typically in line with the Wholesale Price Index. In 2024, the NPPA revised prices for 923 scheduled formulations.

For drugs not on the NLEM, companies can price freely, subject only to competitive market dynamics.

Why this matters for margins: If a company earns 30% of its domestic revenue from price-controlled molecules, an NPPA price cut of 5% directly reduces that revenue by 1.5 percentage points. Investors need to know what share of a company's domestic portfolio sits on the NLEM.

Insurance and government health schemes Out-of-pocket spending remains high in India (approximately 55 to 60% of total health expenditure). Private health insurance has grown significantly but still covers a minority of the population. PMJAY (Pradhan Mantri Jan Arogya Yojana, also called Ayushman Bharat) provides health insurance of up to Rs 5 lakh per family per year to approximately 500 million beneficiaries, making it the world's largest government-funded health insurance programme. PMJAY primarily covers hospitalisation costs, including hospital-dispensed drugs, which creates demand for hospital-channel pharma companies.

---

The Investor's Lens: Where Value Is Created (and Destroyed)

Now that you understand every stage of the chain, here is the summary that matters for investing decisions.

The core insight: brand and patents create value. Distribution and API are necessary but largely commoditised.

The Indian pharma companies that have created the most wealth for investors over 20 years (Sun Pharma, Cipla, Dr. Reddy's) all built large branded domestic prescription businesses (high moat) while also building US generics export businesses (higher growth, but more volatile). The challenge for investors is navigating the US business risk (FDA compliance, price erosion) while the domestic branded business quietly compounds.

Where value gets destroyed:

• Generic competition in the US relentlessly compresses margins on any molecule. The day a new generic is approved, its price often drops 30 to 50% within months as competitors undercut each other.
• FDA Warning Letters can block an entire plant's output from the US market for 12 to 24 months.
• NPPA price cuts reduce domestic margins on essential medicines.
• Working capital: pharma businesses hold significant inventory (raw materials, WIP, finished goods) and have high receivables, especially from export markets.

Understanding these pressures is the foundation of evaluating any pharma company's financial health, which is what the next post in this series covers in detail.

To understand what competitive advantages look like across industries more broadly, see our guide to understanding economic moats. For a primer on reading a company's annual report, see how to read a company's annual report.

---

Key Takeaways

• India is the world's largest supplier of generic medicines by volume, supplying 20% of global generics and exporting to 200-plus countries, in a $68 billion industry growing at 11% annually
• The pharma value chain has at least 10 distinct stages, from drug discovery to the patient's hands, each with different businesses, risks, and investment characteristics
• The US FDA is the most commercially important regulator for Indian pharma exporters: a single Warning Letter can freeze revenue from an entire manufacturing plant
• India's three-tier distribution system (C&F agents, stockists, retail pharmacies) and large MR networks are genuine moats that take years to build
• Branded generics (same molecule as a generic, sold under a brand with doctor relationships) are the backbone of India's domestic pharma market and carry higher margins than pure generics
• Price controls through NPPA affect about 384 essential drug formulations, so investors need to know what share of a company's domestic revenue comes from price-controlled products
• The highest-value parts of the chain are patent-protected originator drugs and branded domestic formulations; the lowest-value are commodity API manufacturing and drug distribution

---

What to Read Next

Now that you understand how the industry works, the next post in this series teaches you exactly which financial metrics to check when evaluating any Indian pharma stock:

• How to Evaluate a Pharma Stock: The Complete Investor's Guide
• The FDA's Naughty List: What Indian Pharma Investors Need to Know — case studies on Warning Letters and Import Alerts across Ranbaxy, Sun Pharma, Cipla, Lupin and more
• Drug Patents, Generic Moats, and India's Global Edge
• How to Read a Company's Annual Report
• Understanding Economic Moats